Investors with Significant Losses in Capricor Therapeutics Should Join Class Action Lawsuit

Class Action Lawsuit for Capricor Therapeutics Investors

In a significant development for shareholders, Robbins LLP has announced a class action lawsuit for individuals who purchased or acquired securities from Capricor Therapeutics, Inc. (NASDAQ: CAPR) between October 9, 2024, and July 10, 2025. This litigation arises from extensive allegations regarding misleading information provided by the company related to its lead drug candidate, deramiocel, which is aimed at treating Duchenne muscular dystrophy (DMD).

Background on Capricor Therapeutics

Capricor Therapeutics is a clinical-stage biotechnology firm focusing on innovative cell and exosome-based therapies. Their flagship product, deramiocel, is derived from cardiosphere-derived cells and is being developed to treat serious health issues such as DMD. However, the company has come under scrutiny regarding the adequacy of data supporting the safety and efficacy of this drug in clinical trials.

Allegations Against Capricor

The lawsuit alleges that, during the class period, Capricor misled investors about the prospects of deramiocel, suggesting that the drug could receive fast-tracked approval for DMD cardiomyopathy. In reality, the company allegedly concealed critical information about the drug's safety and efficacy drawn from a four-year study. A major revelation occurred on July 11, 2025, when Capricor disclosed that it had received a Complete Response Letter (CRL) from the FDA. This letter denied its Biologics License Application, citing insufficient evidence of the drug's effectiveness and the need for additional data.

As a direct consequence, Capricor's stock price plummeted from $11.40 to $7.64, reflecting the severe impact of the company's disclosure on investor confidence.

Participation in the Class Action

Current and former shareholders who suffered losses due to investing in Capricor's securities may qualify to join this class action. Those interested in leading the case can reach out to Robbins LLP. The role of the lead plaintiff is crucial as they represent the collective interests of all members of the class.

It is important to note that participation in the lawsuit is not mandatory for recovery. Individuals can choose to remain as absent class members and still be eligible for any settlements.

Robbins LLP's Commitment to Shareholders

Founded in 2002, Robbins LLP has established itself as a prominent figure in shareholder rights litigation. The firm is dedicated to assisting investors in reclaiming losses, enhancing corporate governance, and holding company executives accountable for misconduct. Their no-win, no-fee policy ensures that shareholders bear no financial burden unless the case is successful.

To stay informed about any developments in the class action against Capricor Therapeutics or to receive updates on other corporate governance issues, interested parties are encouraged to sign up for alerts from Robbins LLP.

In conclusion, investors facing losses from Capricor Therapeutics should consider engaging with Robbins LLP to explore their legal options and possibly join the ongoing class action. This could be a vital step in seeking compensation for their investments.